Table 1.
Clinical data summary.
| Patient | other disease/information | age | sex | TCR | LGL phenotype and purity | ANC | STAT3 | Treatment |
|---|---|---|---|---|---|---|---|---|
| T-LGLL#1 | asymptomatic | 71 | F | αβ | CD3+CD4+ 90% | 2690 | K658F | no |
| T-LGLL#2 | 20 | M | γδ | CD3+CD8+ 24% | 810 | Y640F | no | |
| T-LGLL#3 | celiac | 69 | F | αβ | CD3+CD8+ 81% | 1090 | WT | no |
| T-LGLL#4 | 61 | F | αβ | CD3+CD8+ 90% | 620 | D661Y | no | |
| T-LGLL#5 | lupus | 39 | F | αβ | CD3+CD8+ 35%, CD3+76% | 1000 | WT | no |
| T-LGLL#6 | HA, transf/dep | 58 | M | αβ | CD3+CD8+ 74% | 2130 | Y640F | CsA |
| T-LGLL#7 | 61, 59# | F | β | CD8+ 43% | 1800, 2100# | WT | no | |
| T-LGLL#8 | 60 | F | + marrow | CD3+CD8+CD57+ 15%, CD45+ bright 38% | 490 | WT | no | |
| T-LGLL#9 | 53, 55# | F | + | CD3+CD8+ 24% | 690, 250# | WT | no | |
| T-LGLL#10 | PRCA | 45 | M | γ | CD3+CD8+ 89% | 700 | WT | MTX |
| T-LGLL#11 | 43 | M | αβ | CD3+CD8+ 94% | 1600 | Y640F, prev I659L | MTX | |
| T-LGLL#12 | agranulocytosis | 38 | M | αβ, γδ | CD3+CD8+ 65% | 0 | WT | CsA, pred. |
| T-LGLL#13 | 70 | F | αβ | CD3+ 86% | 200 | D661V | no | |
| T-LGLL#14 | RA | 56 | F | γδ | CD3+CD8+ 84% | 280 | WT | no |
| T-LGLL#15 | transf/dep until CTX | 64 | M | αβ | CD2+CD3+CD8+ 67% | 900 | WT | no; prev. on CTX |
| T-LGLL#16 | 69 | F | αβ | CD3+CD8+ 55%, CD3+CD56+ 45% | 980 | WT | no | |
| T-LGLL#17 | asymptomatic | 61 | M | γ | CD3+CD8+ 55% | 7000 | WT | no |
| T-LGLL#18 | 51 | F | γ | CD3+CD8+ 96%,CD3+CD57+ 67% | 420 | WT | CsA | |
| T-LGLL#19 | asymptomatic | 38 | F | αβ | 20-30%, bone marrow | 1200 | Y640F | no |
| T-LGLL#20 | 46 | M | αβ | CD3+CD8+ 56%, CD3+CD16+ 34%, CD3+CD57+ 51% | 1000 | Y640F | no | |
| T-LGLL#21 | RA | 34 | F | * | CD3+ 93%, CD8+ 32% | 200 | Y640F | Plaquenil, pred. |
| T-LGLL#22 | stable disease | 64 | F | no data | CD3+CD8+ 30% | 3538 | Y640F | no |
| T-LGLL#23 | 23 | F | αβ | CD3+CD8+ 63%, CD3+CD57+ 29% | 1100 | Y640F | no | |
| T-LGLL#24 | 65 | F | + | CD3+CD8+ 93%, CD3+CD57+ 61% | 730 | D661Y | no | |
| T-LGLL#25 | asymptomatic | 79 | M | αβ | CD3+CD8+CD57+ 44% | 1623 | Y640F | no |
Abbreviations: methotrexate (MTX), Cytoxan (CTX), cyclosporine A (CsA), prednisone (pred.), rheumatoid arthritis (RA), pure red cell aplasia (PRCA), hemolytic anemia (HA), transfusion dependent (transf/dep).
Age = patient age at the time of the sample collection.
Treatments listed include only immunosuppressants for LGLL and/or autoimmune disease. Other medications the patients may be taking are not listed.
Clinical data correspond to laboratory diagnostic tests performed on the date of blood collection or the closest date for which this information is available.
TCR and flow data are from peripheral blood unless otherwise specified.
TCR positivity is sometimes there, sometimes not # data correlate to A, B samples respectively in Fig. 1.